Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Buchholz TA, et al. Among authors: singletary se. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):880-8. doi: 10.1016/s0360-3016(02)02850-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 12095553
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Buzdar AU, et al. Among authors: singletary se. J Clin Oncol. 2005 Jun 1;23(16):3676-85. doi: 10.1200/JCO.2005.07.032. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738535 Clinical Trial.
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
Montero AJ, Rouzier R, Lluch A, Theriault RL, Buzdar AU, Delaloge S, Bermejo B, Le M, Kau SW, Dunant A, Arriagada R, Spielmann M, Garcia-Conde J, Sahin AA, Singletary SE, Hortobagyi GN, Valero V. Montero AJ, et al. Among authors: singletary se. Cancer. 2005 Jul 15;104(2):229-35. doi: 10.1002/cncr.21182. Cancer. 2005. PMID: 15937910 Free article.
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Hanrahan EO, et al. Among authors: singletary se. Cancer. 2006 Jun 1;106(11):2327-36. doi: 10.1002/cncr.21906. Cancer. 2006. PMID: 16639731 Free article. Clinical Trial.
Selective use of sentinel lymph node surgery during prophylactic mastectomy.
Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Boughey JC, et al. Among authors: singletary se. Cancer. 2006 Oct 1;107(7):1440-7. doi: 10.1002/cncr.22176. Cancer. 2006. PMID: 16955504 Free article.
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Buzdar AU, et al. Among authors: singletary se. Clin Cancer Res. 2007 Jan 1;13(1):228-33. doi: 10.1158/1078-0432.CCR-06-1345. Clin Cancer Res. 2007. PMID: 17200359 Clinical Trial.
286 results